About Equator Therapeutics
Equator Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2019. Mitochondria-targeting drugs are developed to burn calories and boost metabolism. Equator Therapeutics has raised $125 thousand across 2 funding rounds from investors including HHS and Y Combinator. The company has 3 employees. Its chief executive, as recorded, is Jonah Sinick. Equator Therapeutics offers products and services including Thermogenesis Drug and High-Throughput Assays. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Obesity. Its competitors include Altimmune, Carmot and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Equator Therapeutics was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where mitochondria-targeting drugs are developed to address metabolic disorders. Research efforts center on enhancing calorie expenditure and improving overall metabolic function through innovative therapeutic approaches. The company is led by CEO Jonah Sinick, with activities conducted primarily in the U.S.
- Headquarters San Francisco, United States
- Employees 3
- SectorsHealthcare
- Email••••••••
- Website equatortherapeutics.com
- Social LinkedIn
- Legal Name Equator Therapeutics
- Total Equity Funding$125K (USD)
in 2 rounds
- Latest Funding Round$1.91M (USD), Grant
Sep 2021
- InvestorsHHS
& 1 more
- Employee Count3
Products & Services of Equator Therapeutics
Equator Therapeutics offers a comprehensive portfolio of products and services, including Thermogenesis Drug and High-Throughput Assays.
Stimulates mitochondrial heat production for sustained weight loss.
Identifies compounds for safe thermogenic activation in mitochondria.
Funding Insights of Equator Therapeutics
Equator Therapeutics has successfully raised a total of $125K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.91 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125,000
- Total Rounds 2
- Last Round Grant — $1.91M
- First Round $125,000
(Jun 2020)
- Investors Count 2
All 2 funding rounds of Equator Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $1.91M | Grant | – | – | |
| Jun 2020 | $125,000 | Seed | – | Y Combinator | – |
2 investors in total: 2 institutional.
Investors in Equator Therapeutics
Equator Therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Equator Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Equator Therapeutics
9 people are tracked at Equator Therapeutics (4 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Jonah Sinick | CEO | Leadership |
Junji Suzuki | Director, Japan Branch | Leadership |
Yuriy Kirichok | Co-Founder, Chief Scientific Officer | Leadership |
Katherine Widdowson | Head, Medicinal Chemistry | Leadership |
John Amatruda | Scientific Advisor | Board & advisors |
Michael Grabe | Advisor | Board & advisors |
Andrea Dunaif | Advisor | Board & advisors |
Gerald Shulman | Advisor | Board & advisors |
Simon Vu | Scientist | Team |
Complete people profiles for Equator Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Equator Therapeutics
3 dated milestones of Equator Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Equator Therapeutics is founded.
- Funding First funding round of $125K.
- Funding Latest funding round, Grant, of $1.9M.
Competitors of Equator Therapeutics
Equator Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Altimmune, Carmot and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Equator Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Equator Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Equator Therapeutics
Equator Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Equator Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Jonah Sinick is the CEO of Equator Therapeutics, as recorded in our data.
Equator Therapeutics is a funded company, having raised a total of $125K across 2 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Jun 2020.
Equator Therapeutics has 3 employees.
Equator Therapeutics was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where mitochondria-targeting drugs are developed to address metabolic disorders. Research efforts center on enhancing calorie expenditure and improving overall metabolic function through innovative therapeutic approaches. The company is led by CEO Jonah Sinick, with activities conducted primarily in the U.S.
Equator Therapeutics's top competitors include BioAge Labs, Carmot and Altimmune.
Equator Therapeutics offers Thermogenesis Drug and High-Throughput Assays.
Equator Therapeutics has 2 investors. Key investors include HHS, and Y Combinator.
Equator Therapeutics operates through Equator Therapeutics.